Catalyst Biosciences, Inc.: Catalyst Biosciences Completes F

Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5

Related Keywords

China , Ying Luo , Liaoning , Beijing , Japan , Tokyo , United States , Canada , Chinese , Trisha Colton , Nassim Usman , Augustine Lawlor , Raymond James , Thomas Eastling , Gibson , Catalyst Biosciences Inc , Nasdaq , Group Ltd , Group In Subsequent Transaction , Dunn Crutcher , Securities Exchange , Company Or Catalyst , Leadership Organization , Herrington Sutcliffe , Pharma Company , Acquire Controlling Interest , China Based Commercial Pharma Company , Special Dividend , Contingent Value Right , Meeting Planned , Host Conference Call Today , Beijing Continent , Mainland China , Catalyst Board , Andrea Hunt , Seline Miller , Chief Executive Officer , Interim Chief Financial Officer , Seriesx Preferred Stock , Preferred Stock , Business Combination , Business Combination Agreement , Catalyst Common Stock , Catalyst Biosciences , Securities Exchange Act , Securities Act , Minority Holders , Annual Report , Quarterly Reports , Current Reports , Additional Information Will , Catalyst , Iosciences , Ompletes , First , Steps , Reverse , Berger , Plan ,